GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast on Wednesday, April 3rd at 10:10 AM ET
4 月 3 日星期三网络直播第三方 美国东部时间上午 10:10
LA JOLLA, CA, March 28, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET.
加利福尼亚州拉霍亚，2024年3月28日——GRI Bio, Inc.（纳斯达克股票代码：GRI）（“GRI Bio” 或 “公司”）今天宣布，该公司正在推进用于治疗炎症、纤维化和自身免疫性疾病的自然杀伤性T（NKT）细胞调节剂创新产品线 Marc Hertz，博士，首席执行官 GRI Bio 的，将出席 MedInvest 生物技术和制药投资者会议 将于美国东部时间2024年4月3日星期三上午10点10分在纽约州纽约市举行。
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
除演讲外，管理层还可以与注册参加会议的合格投资者社区成员进行一对一的会议。有关会议的更多信息，请访问 会议网站。
A live webcast of the event will be available on the Events page of the Investors section of the Company's website (www.gribio.com).
A 网络直播 该活动的内容将在 活动 的页面 投资者 公司网站的部分（www.gribio.com)。
About GRI Bio, Inc.
关于 GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. iNKT cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of IPF, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of SLE. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
GRI Bio是一家临床阶段的生物制药公司，致力于从根本上改变炎症、纤维化和自身免疫性疾病的治疗方式。GRI Bio的疗法旨在靶向NKT细胞的活性，NKT细胞是炎症级联早期的关键调节剂，以中断疾病进展并恢复免疫系统的动态平衡。NKT 细胞是与生俱来的 T 细胞，共有 NK 和 T 细胞的特性，是先天免疫反应和适应性免疫反应之间的功能纽带。inKT 细胞在传播炎症和纤维化适应症中观察到的损伤、炎症反应和纤维化方面起着关键作用。GRI Bio的主要项目 GRI-0621 是InKT细胞活性的抑制剂，正在开发为一种用于治疗IPF的新型口服疗法，IPF是一种严重的疾病，其需求尚未得到满足。该公司还在开发用于治疗系统性红斑狼疮的新型2型NKT激动剂产品线。此外，GRI Bio拥有超过500种专有化合物的库，有能力为不断增长的管道提供燃料。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
投资者联系人：
JTC Team, LLC
珍妮·托马斯
(833) 475-8247
GRI@jtcir.com
